Websites, domains, hosts that links to biogen.com

Information about choosing a treatment for relapsing-remitting MS that fits with your life goals.

バイオジェンの脊髄性筋萎縮症（SMA)治療薬「スピンラザ」の情報サイトです。

Cutting Edge Information provides decision support for pharma and medical device leaders with primary data, benchmarking reports & customized research

Biogen ist ein Biotechnologie-Unternehmen, das sich der Entwicklung neuer Therapien verschrieben hat, um das Leben von Patienten mit neurologischen, hämatologischen und Autoimmunerkrankungen zu verbessern. Erfahren Sie mehr.

The official Healthcare Professional site for Tecfidera® (dimethyl fumarate), a delayed-release capsule treatment. Find information to help your patients here.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.

Biogen er en bioteknologisk virksomhed, der bruger den nyeste videnskab til udvikling af nye behandlinger, som kan forbedre livskvaliteten hos mennesker, der lever med neurologiske, hæmatologiske og autoimmune sygdomme.

了解脊髓性肌肉萎縮症（SMA），一種造成失去動作功能以及肌肉萎縮的神經肌肉疾病，以及SMA患者的照護選項。

Learn about ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein].

Above MS from Biogen provides tools, tips, and inspiration for your multiple sclerosis—and more.

Con una misión diseñada para salvaguardar el bienestar y la salud de los pacientes, Laboratorios BIOGEN de Colombia, desarrolla medicamentos de alta calidad, para diversas acciones terapéuticas fundamentales, siempre enmarcadas en el ámbito de la innovación, la investigación y la competitividad. Son mas de tres décadas de crecimiento, diseñando programas de interés clínico con un enfoque ético que garantiza la seguridad de cada uno de sus productos.

Biogen er et bioteknologiselskap dedikert til å utvikle nye behandlingsalternativer for å forbedre livet til pasienter som lever med nevrologiske, hematologiske og autoimmune sykdommer.

Learn about Biogen treatment options for people living with relapsing multiple sclerosis (MS).

Learn about TYSABRI® (natalizumab), a prescription medicine for adults, including dosing information, how it works, copay information and support resources.

Consider once-a-month ZINBRYTA® (daclizumab) if you’re looking for another treatment option. Find instructional videos & more here. See full safety & Boxed Warning.

The official Healthcare Professional site for PLEGRIDY® (peginterferon beta-1a). Find information for your patients here.

Life Science Association of California, Biocom represents over 750 biotechnology, pharmaceutical, digital health and medical device/diagnostic companies.

多発性硬化症に関するあらゆる情報のご提供を通じて患者さんやご家族の皆さまをサポートします。

Web del Observatorio Esclerosis Múltiple, una plataforma que ofrece el conocimiento de libre acceso a Internet sobre esta enfermedad neurológica.

Biogen develops, manufactures and markets innovative therapies for patients living with serious neurological, autoimmune and rare diseases.

Above MS from Biogen provides tools, tips, and inspiration for your multiple sclerosis—and more.

If you are worried about you or a loved ones memory getting worse, if it impacts your daily life it could be a sign of Alzheimers

Find out more information about AVONEX® (interferon beta-1a), including how it is thought to work, how to take it and how to get started.

Learn about TYSABRI (natalizumab), including clinical experiences, mechanism of action, potential adverse reactions, and HCP resources. See full ISI & Boxed Warning.

ICMN 2018

Feeling confused, getting lost and forgetting words are all early signs of Alzheimer's disease. Read more and take the Alzheimer's screening test.

Discover Tecfidera® (dimethyl fumarate). Get information on clinical studies, a copay program, and patient support services.

Na Biogen, descobrimos, desenvolvemos, fabricamos e comercializamos terapias inovadoras para pessoas que vivem com doenças graves, neurológicas, autoimunes e raras.

Biogen entwickelt, produziert und vertreibt innovative Medikamente für Menschen mit schweren neurologischen, Autoimmun- und seltenen Erkrankungen.

Learn about SPINRAZA® (nusinersen), an FDA-approved treatment from Biogen. Find out more at SPINRAZA.com

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.

Join us for the 2017 power wheelchair World Cup, held in Kissimmee, Florida July 5-9. Ten teams from across the planet will compete for the title of world champion.

Register to receive notifications about upcoming clinical studies in your area.

Just another WordPress site

Above MS from Biogen provides tools, tips, and inspiration for your multiple sclerosis—and more.

We've been coaching and training communication skills for over 50 years. We will help you speak with confidence. From leaders of countries to companies to individuals.

Learn about spinal muscular atrophy (SMA), a neuromuscular disease that causes loss of motor function and muscle atrophy, and care options for individuals with SMA

Recovering scientist turned early stage VC | A biotech optimist fighting gravity

Deutsche Selbsthilfegruppe für Muskelkranke und speziell für die Spinale MuskelAtrophie,Unterstützung Forschung, Netzwerk, Direkthilfe für Betroffene

Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.

Find hospitals, National Hospital provides directories of hospitals, physicians, associations, government resources, & more.

Information for healthcare providers about ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein].

Biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for serious neurological, autoimmune and rare diseases.

Information for healthcare professionals about SPINRAZA® (nusinersen), an FDA-approved treatment from Biogen.

BI, Analytics, Data Integration, Security Solutions delivered in the Modern data center for Healthcare, Higher Ed, Financial Services, Pharma & Retail

Learn about ZINBRYTA® (daclizumab), an injection treatment. Find information to determine if it’s the right option for patients. See full ISI & Boxed Warning.

Bei Biogen entdecken, entwickeln, produzieren und vertreiben wir innovative Medikamente für Menschen mit schweren neurologischen, hämatologischen und Autoimmun-Erkrankungen

Biogen entwickelt, produziert und vermarktet innovative Therapien für Patienten seltenen, schweren neurologischen und Autoimmun-Erkrankungen.

Learn more about the benefits and risks with PLEGRIDY® (peginterferon beta-1a) and how to get started.

SIMPLE. FAST. INTUITIVE. FLEXIBLE. Generis CARA User Interface for Documentum, Oracle WebCenter and Alfresco with a full configuration toolsuite. Winner...

バイオジェンは、神経疾患、血液疾患、自己免疫疾患の患者さんの生活を向上させる新たな治療法の開発に尽力するバイオテクノロジー企業です。もっと読む。